Development of pulmonary infiltrates with respiratory symptoms in patients with advanced cancer presents a diagnostic challenge. We describe a case of a patient who developed progressive respiratory failure and bilateral lung infiltrates whilst receiving docetaxel chemotherapy for advanced lung cancer. After excluding other aetiologies, he was treated for docetaxel-related pneumonitis with corticosteroid therapy. Interstitial pneumonitis is a rare complication of Docetaxel chemotherapy but needs to be recognised and treated early, as it is associated with high mortality rates. We describe the presentation, differential diagnoses and possible mechanisms associated with drug-related pneumonitis.
INTRODUCTION
Development of pulmonary infiltrates with respiratory symptoms in patients with advanced cancer presents a diagnostic challenge. We describe a case of a patient who developed progressive respiratory failure and bilateral lung infiltrates whilst receiving docetaxel chemotherapy for advanced lung cancer.
CASE REPORT
A 70-year old man first presented with left sided chest pain in September 2002. Chest x-ray performed by his family doctor revealed a right mid-zone nodule. He was further evaluated with a computed tomography (CT) thorax, which demonstrated a 2 cm right upper lobe mass, with no other sites of disease. He underwent a right upper lobectomy in November 2002, and histology revealed a 2.5-cm lung adenocarcinoma. Mediastinal and hilar lymph nodes were negative for cancer, hence he was staged as a T1N0M0 lung adenocarcinoma. His past medical history was that of hypertension for the past 10 years, ischaemic heart disease for which he had undergone coronary artery bypass grafting in 1999, and hyperlipidemia. He was an ex-smoker with a 30-pack year history and had stopped smoking 10 years previously.
In 2009, he was diagnosed with prostate carcinoma, and a routine staging CT scan was performed. This revealed a large mass in the medial segment of the middle lobe measuring 6.4 x 4.1cm, with narrowing of medial segment of the airway, and with involvement of the left atrium where a thrombus measuring 3.0 x 2.6 cm was visualised within it. Bronchoscopy and biopsy was done which confirmed adenosquamous carcinoma, further epidermal growth factor-receptor mutational testing on the biopsy was negative. Due to the local extent of the tumour, he was deemed unsuitable for surgical resection and for radical radiotherapy. Hence, he was commenced on palliative chemotherapy with gemcitabine and carboplatin in September 2010. A repeat scan after two cycles showed an increase in atrial component of the tumour mass. As there was no significant response, he was switched to second line weekly docetaxel chemotherapy in November 2010, administered at a dose of 25mg/m 2 on days 1, 8 and 15 of a 28-day cycle. He tolerated cycle 1 of chemotherapy reasonably well, but during day 15 of his second cycle of chemotherapy, he started to complain of high fever and cough. Chest x-ray was unremarkable but chemotherapy was withheld and antibiotics were prescribed empirically. Four days later, on day 19 of his second cycle, his Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 fever and cough persisted, and were now associated with breathlessness and he was admitted for further evaluation. At this point he was tachycardic, and oxygen saturations were 76% on room air, although blood pressure was maintained. Chest x-ray showed an increase in ill-defined reticular changes in bilateral lungs. A 12-lead electrocardiogram revealed sinus tachycardia, but no evidence of acute coronary syndrome, furthermore, cardiac enzymes were negative. He was commenced on intravenous antibiotics but his condition deteriorated overnight and he was put on 100% oxygen, and his condition stabilised with an oxygen saturation of 94%.
Blood cultures and sputum cultures showed no significant bacterial growth and hence, antibiotics were discontinued. A trial of intravenous diuretics was administered to treat fluid overload but with minimal improvement of his condition. A CT pulmonary angiogram was performed on day 2 of admission, this demonstrated a large mass-like filling defect measuring 4.8 cm within pulmonary vein confluence and right middle lobe mass in close relation to this mass; consistent with his previous CT scan, however, additionally, there was significant and diffuse ground glass opacities bilaterally. Significantly, there was complete sparing of the right middle lobe from the ground glass changes (Fig 1) . In view of the possibility of drug-induced pneumonitis, empiric corticosteroid therapy with dexamethasone was commenced. Bronchoscopic evaluation was not carried out due to his critical condition, and due to his and his family's wishes for no intubation and mechanical ventilation in the event of further deterioration. He showed gradual improvement and his oxygen requirements were tailed to 2L. intranasal oxygen upon discharge. A repeat CT done one month later in January 2011 showed interval resolution of diffuse ground glass changes and interval decrease in size of middle lobe mass, with reduced obstruction of middle lobe bronchus, and a stable left atrial thrombus. Unfortunately, he was readmitted in February 2011 following a fall and was noted to be hypotensive, breathless and febrile. Chest x-ray showed new focal consolidative changes in the right lower lobe. He was commenced on antibiotics, high flow oxygen but his condition deteriorated rapidly and he passed away two days later.
DISCUSSION
The development of pulmonary infiltrates, associated with respiratory symptoms and progressive respiratory failure in cancer patients, particularly those who are undergoing chemotherapy, is a difficult diagnostic problem. Differential diagnoses include infection, cardiogenic oedema, radiation pneumonitis, pulmonary haemorrhage, lymphangiitic carcinomatosis, or drug-related interstitial lung disease. be visualised on CT scan, with or without thickening of bronchovascular bundles, thickening of isolated interstitial lines and presence of polygonal lines 1, 2 . Analysis of bronchoalveolar fluid may reveal presence of tumour cells, whilst lung biopsy will usually help confirm the diagnosis. In our patient, there was no prior history of lymphangitis noted and CT scan did not show typical characteristics. Despite his previous cardiac history, there were no other signs of heart failure; and a trial of diuretics was ineffective. Our patient had not received any radiation prior to onset of current episode. He also denied exposure to any other drugs or antigens known to be associated with pulmonary toxicity.
Thus, the diagnosis of docetaxel induced pneumonitis was made based on several criteria: (i) the history of docetaxel administration and its known association with pneumonitis, albeit rare;
(ii) presence of a clinical and imaging pattern consistent with docetaxel-pneumonitis;
(iii) the exclusion of other significant lung pathology and (iv) significant clinical improvement following discontinuation of the suspected drug (and initiation of steroids).
Docetaxel (Taxotere, Aventis, France) is an antineoplastic agent belonging to the taxane family, and is derived semi-synthetically from the European yew (Taxus baccata). It has activity against a broad range of cancers such as breast, ovarian, bronchial, gastric, bladder, head and neck, and prostate carcinomas. Together with Paclitaxel, it is an anti-tubulin drug that works by promoting assembly of tubulin and microtubules and stabilises microtubule activity against depolymerisation, thereby blocking cells in the metaphase of the cell cycle. Docetaxel is known to have side effects such as myelosuppression, alopecia, asthenia, neurosensory problems and fluid retention. Docetaxel is formulated in a nonionic surfactant polysorbate 80 (Tween 80), the presence of which has been implicated in acute hypersensitivity reactions 3 . Unique to docetaxel is a fluid retention syndrome attributed to capillary leak, where retention of fluid in peripheral tissues, pleural or peritoneum gradually develops after the patient has received several cycles of docetaxel, which may lead to oedema, and/or pleural effusions 4 .
Pulmonary complications after docetaxel administration are uncommon, but have been reported at an incidence between 1-3% from several phase II and phase III trials in non-small cell lung cancer [5] [6] [7] . Several case reports have demonstrated that patients typically present with acute onset of respiratory symptoms such as breathlessness and cough, and may also report low grade fever. Development of pneumonitis appears to be unrelated to the cumulative dose of Docetaxel or duration of therapy or treatment response. The onset of symptoms may occur after just one cycle of chemotherapy 8, 9 or after two or more doses [9] [10] [11] [12] and even as late as after six cycles of chemotherapy 10 . From various case reports, the natural history comprises progressive respiratory failure, which may necessitate mechanical ventilation. Administration of corticosteroid therapy improves respiratory function and may lead to eventual recovery 8, 11 , but in spite of aggressive measures, not all patients recover, and mortality rates are high. Certain combination treatments appear to be associated with higher risk of pneumonitis, such as a combination of docetaxel and gemcitabine chemotherapy 13 and concomitant radiation therapy and docetaxel 14 .
Whilst the likelihood of developing drug-induced interstitial lung disease is largely idiosyncratic and unpredictable, in general, both extremes of age appear more susceptible 15 . Certain races may be more susceptible to developing toxicity with certain drugs, for example, the risk of drug-induced pneumonitis related to Gefitinib administration is significantly higher in the Japanese population 16 . Genetic polymorphisms may also explain why particular patients have the expected response to pharmacotherapy whilst others experience toxicity (or therapeutic failure). The dose of drug administered may be a risk factor for drug related interstitial pneumonitis for certain drugs, such as bleomycin 17 . Drug interactions with other concomitant drugs or treatments may increase the risk of pulmonary toxicity, as with docetaxel and gemcitabine 13 , or concomitant radiotherapy 14 . Renal dysfunction may increase risk of pulmonary toxicity, as noted with bleomycin 17, 18 , whilst prior smoking history may also increase risk of bleomycin related pulmonary toxicity 19, 20 The exact mechanisms by which cytotoxic agents cause lung injury have not been completely elucidated, however two main mechanisms are recognised 21 . Cytotoxic drugs can cause direct injury to pneumocytes and/or alveolar capillary endothelium via formation of reactive oxygen species, or via impairment of alveolar repair mechanisms, or release of cytokines. Alternatively, some anticancer drugs are able to induce immunomodulation or induce an immune cascade leading to immune-mediated lung toxicity via drug-specific antibodies or drug-specific T-cells. Deposition of antigen-antibody complexes may trigger an inflammatory response leading to pulmonary oedema and interstitial lung disease, which may indirectly contribute to lung injury by altering the normal pulmonary immunologic balance.
In our patient, the right middle lobe was completely spared from pneumonitis. The presence of a large bulky tumour at the pulmonary vein confluence may have led to disruption of the bronchial circulation into the right middle lobe, and hence may have affected delivery of docetaxel chemotherapy into the affected lobe, although this is not visibly seen on the CT scan. Alternatively, the tumour, given its location and size, may have led to gradual compression of the pulmonary vein draining the middle lobe, leading to segmental pulmonary venous hypertension. This would then lead to backward transmission of the pressure causing pulmonary capillary congestion in that particular lung segment and theoretically result in decreased pulmonary perfusion within that lung segment. This phenomenon can be seen on a larger scale when there are left heart disorders such as valvular mitral stenosis, which can lead to pulmonary venous hypertension. This may explain why the drug-induced pneumonitis preferentially affects the rest of the lungs whilst sparing the tumour-associated lobe.
In conclusion, cancer patients who present with progressive respiratory failure and associated infiltrative changes on radiology whilst ongoing chemotherapy, should be carefully evaluated to exclude progressive disease, pulmonary infection and/ or cardiogenic oedema, before a diagnosis of drug-induced pulmonary toxicity is made.
Non-invasive tests such as chest x-ray, CT scans, echocardiography, pulmonary function tests and blood gases can determine the pattern of pulmonary disease present. Bronchoscopy with lavage and biopsy may be performed to evaluate for infection and lymphangitis. The most effective way of managing pulmonary toxicity associated with chemotherapeutic agents is prophylaxis if possible. Drug doses and cumulative thresholds should be followed. Pre-medications should be administered as per protocol. During therapy, monitoring of vital signs should be performed routinely. Nurses and doctors managing such patients should be aware of, and vigilant in assessing any new symptoms and have a low threshold for further evaluation. In the event of suspected toxicity, withdrawal of the offending agent is mandatory and consideration of a trial of corticosteroids, although the optimal dose and duration of steroid therapy is not known. Corticosteroids require a slow and careful tapering schedule, since clinical deterioration after tapering has been reported. If exacerbation of symptoms occurs, higher doses of steroids may be needed for a more prolonged period. Supportive care with bronchodilators, expectorants, antibiotics, bed rest, oxygen and opioids can be beneficial for symptom relief.
